Recent Advances in Understanding the Pathogenesis of Atherosclerosis in CKD Patients

A need exists for developing new therapies to improve cardiovascular outcomes in end-stage kidney disease. Three new areas that address novel pathophysiological mechanisms and/or therapeutic approaches toward cardiovascular events in chronic kidney disease patients include the use of an anti-inflammatory agent, the role of catalytic iron, and protein carbamylation. In preliminary studies, hydroxychloroquine, which has multiple anti-inflammatory properties, preserved vascular compliance for the aorta and major vessels, as well as reduced the extent of severity of atherosclerosis in ApoE−/− mice.

Source: Journal of Renal Nutrition - January 1, 2015 Category: Urology & Nephrology Authors: Sudhir V. Shah, Ashutosh M. Shukla, Chhanda Bose, Alexei G. Basnakian, Mohan Rajapurkar Tags: Icurt Proceedings Source Type: research